ExploreInterventionAndrogen deprivation therapy
Intervention

Androgen deprivation therapy

Also known as: Androgen deprivation therapy Androgen deprivation therapy (procedure) Androgen deprivation therapy with leuprolide acetate (22.5 mg every 3 months) plus bicalutamide (first month) for 6 months in men with non-metastatic prostate cancer PCa
15 findings 1 paper 10 related entities View in graph →

Related entities

conditions
outcomes
populations
studys

Findings (50)

None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
null

Men undergoing ADT displayed a trend toward worsening anxiety as assessed by STAI state scores that did not reach statistical significance, while STAI trait scores showed no change.

Effect: null; 2.34; CI: 95% CI = -0.09 to 4.76

Size: 2.34 CI: 95% CI = -0.09 to 4.76
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82
None
adverse

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Size: 0.93 CI: 95%CI= 0.04 to 1.82

Papers (1)